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Abstract
Interleukin-10 (IL-10) initiates potent anti-inflammatory effects via activating its cell surface receptor, composed of IL-10R1
and IL-10R2 subunits. The level of IL-10R1 is a major determinant of the cells’ responsiveness to IL-10. Here, via a series of
biochemical analyses using 293T cells reconstituted with IL-10R1, we identify the latter as a novel substrate of bTrCP-
containing ubiquitin E3 ligase. Within the intracellular tail of IL-10R1, a canonical (
318DpSGFGpS) and a slightly deviated
(
369DpSGICLQEP) bTrCP recognition motif can additively recruit bTrCP in a phosphorylation-dependent manner. bTrCP
recruitment leads to ubiquitination, endocytosis and degradation of IL-10R1, subsequently reducing the cellular
responsiveness to IL-10. Our study uncovers a novel negative regulatory mechanism that may potentially affect IL-10
function in target cells under physiological or pathological conditions.
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Introduction
Higher organisms have evolved sophisticated anti-inflammatory
systems to prevent immuno-pathology. Among these systems,
interleukin-10 (IL-10) exhibits a critical and indispensible role in
limiting inflammation under numerous conditions (reviewed in
[1]). Mechanistically, IL-10 is thought to mainly target innate
immune cell types and antigen-presenting cells, partly via its
powerful action in inhibiting pro-inflammatory cytokine synthesis.
In addition, direct effects of IL-10 in suppressing T cells’ function
[2,3,4], or on the development of T regulatory lineages, have also
been reported extensively [5,6,7]. Parallel to the diversity of IL-10
target cell types, IL-10 production itself can be attributed to
immune cells of multiple lineages (reviewed in [8]). The wide
distribution of IL-10 signaling circuit in the immune system
confers multiple dimensions to the IL-10-associated immuno-
regulation, which fittingly reflects the latter’s role as a fundamental
safeguard against the ‘unwanted’ aspects of immunity.
Based upon IL-10’s potent immune-suppressive activity in cell
culture and animal models, the potential of recombinant IL-10 in
treating inflammatory diseases such as Crohn’s disease and
rheumatoid arthritis has long been considered. However, such a
concept was only met with limited success in clinical trials
(reviewed in [9]). The lack of significant therapeutic effects might
result from the insufficient amount of recombinant IL-10 at the
site of inflammation, as studies in animal models have shown the
importance of a localized delivery of IL-10 in its efficacy of
suppressing tissue-specific inflammation [10,11]. In addition, since
IL-10 also has some stimulating activities on the humoral
[12,13,14] and cytotoxic [15,16] arms of immunity, inability to
control these confounding factors when systemically delivering IL-
10 may have contributed to the dissatisfying results in such clinical
trials. Therefore, the pharmacological manipulation of intracellu-
lar pathways that regulate IL-10 response appears to be a rational
alternative to the usage of the recombinant ligand. Furthermore, it
has been shown that in cells from arthritis joints or cells pre-treated
with certain pro-inflammatory stimuli, IL-10 responses were
indeed compromised [17,18,19,20]. Such data suggest that a
reduced action by IL-10 in target cells may be a critical pathogenic
event underlying the development and/or progression of certain
inflammatory conditions. In this regard, further identification of
negative regulators of IL-10 signaling and exploration of their
physiological/pathological roles will have significant therapeutic
implications.
The molecular mechanisms whereby IL-10 mediates its
biological function have been extensively studied. IL-10 activates
its cell surface receptor complex, composed of IL-10R1 and IL-
10R2 subunits. Both receptor subunits are critical for IL-10
functions [21,22,23]. The binding of IL-10 to its receptor results in
activation of receptor-associated tyrosine kinases of Janus kinase
family, Jak1 and Tyk2, which in turn lead to phosphorylation of
two tyrosine residues (Y427, Y477 in mouse and Y446, Y496 in
human) on IL-10R1. These phosphorylated tyrosine residues
recruit Stat3 to the activated receptor, which causes the
subsequent phosphorylation and activation of the latent transcrip-
tion factor [24,25]. There is strong evidence suggesting that Stat3,
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stimulation, are critical to the ligand’s anti-inflammatory activity
[26,27,28]. Therefore, regulatory mechanisms affecting the
signaling events upstream of Stat3 can profoundly impact IL-10-
mediated immune suppression.
IL-10 receptor complex represents the only ligand-specific
signaling component within the proximal IL-10 pathway. Between
the two receptor subunits, only IL-10R1 is exclusive for IL-10
signaling [29]. In contrast, IL-10R2 can form complexes with
other cytokine receptor subunits and function also as part of the
receptors for IL-22, IL-26 and IFNl [29]. Intriguingly, cellular
responsiveness to IL-10 has been positively correlated with the
levels of IL-10R1 expression in different cell types [30], suggesting
that the regulation of IL-10R1 expression levels might be a key
mechanism modulating IL-10 function in vivo.
Earlier studies have demonstrated that the ligand-induced
degradation of cell surface IL-10R1 functions to terminate IL-10
signaling [31,32]. Although the detailed mechanisms underlying
such regulation are yet to be established, these very studies have
pointed to a role of protein stability in determining the levels of IL-
10R1 expression and, subsequently, the magnitudes of cellular
responsesto IL-10.IL-10R1belongsto the class IIcytokine receptor
family that also includes type I IFN receptor subunits (reviewed in
[29]). Previous studies have comprehensively unveiled that the
recruitment of SCF
bTrCP ubiquitin E3 ligase to type I IFN receptor
serves as a convergence point of multiple signaling pathways that
regulate the latter receptor’s stability [33,34,35,36,37,38,39]. In the
presentstudy,wetestedthepossibilityofIL-10R1alsobeingatarget
of bTrCP-mediated ubiquitination and down-regulation. Our data
provide biochemical evidence supporting the involvement of such a
novel regulatory mechanism in modulating the magnitudes of
cellular responses to IL-10.
Results
We initially sought to use database search to identify candidate
proteins that may represent novel bTrCP substrates. Many
established SCF
bTrCP substrates (Fig. 1A, left) possess the
DSG(X)2+nS consensus motifs (referred to as DSG motifs
hereafter), where the two serine residues serve as bTrCP
recognition sites when phosphorylated [40]. We used the above
consensus sequence in our search of the Scansite database (http://
scansite.mit.edu/ [41]). We noticed that human interleukin 10
receptor subunit 1 (IL-10R1) possesses such a motif
(
318DSGFGS
323), which is conserved among various mammalian
species (Fig. 1A, right). Since IL-10R1 belongs to the class II
cytokine receptor family [29], which also includes type I interferon
receptor subunit 1 (IFNAR1), an established substrate of SCF
bTrCP
[33], we hypothesized that IL-10R1 may be subjected to a similar
mode of regulation.
To examine the potential regulation of IL-10R1 by bTrCP, we
utilized human embryonic kidney 293T cells as our major
experimental system. These cells are devoid of functional
endogenous IL-10R1 [42]. Transfected IL-10R1 appears on the
Western blot as a 120 kDa form and a 100 kDa form (the arrow
head and the asterisk in Fig. 1B), likely to be caused by different
levels of glycosylation[43]. Viacell surface IP experiment, we found
that the cell surface IL-10R1 runs at 120 kDa (Fig. 1B). We
therefore will refer to the 100 kDa and the 120 kDa form as the
immature (im) and the mature (m) IL-10R1 respectively. Since
bTrCP interacts with its substrates to trigger their ubiquitination
[40], we examined whether we could detect interaction between IL-
10R1 and bTrCP, when the two are co-transfected in 293T cells. In
such a system, HA-bTrCP2 could clearly co-immunoprecipitate
(co-IP) with the C’-terminally Flag-tagged IL-10R1 (Fig. 1C, left),
and a similar result was found with the reverse experiment (Fig. 1C,
right). Notably, the matureform(120 kDa)of IL-10R1 was found to
be associated with HA-bTrCP2 to a greater extent than the
immature form (Fig. 1C, right: the arrow head and the asterisk),
suggesting that bTrCP may preferentially target the mature IL-
10R1. Interestingly, treatment of the cells with IL-10 did not
considerably affect the levels of co-immunoprecipitated HA-
bTrCP2 and IL-10R1-Flag (compare lane 2 and 3 in both left
and right panels of Fig. 1C). Therefore, distinct from an established
model applicable to several other cytokine receptors where ligand
stimulation promotes bTrCP recruitment to the receptor
[33,44,45], such an effect by IL-10 was not observed on ectopically
over-expressed IL-10R1 used in the current study.
To further confirm that the ligand-independent interaction
between IL-10R1 and bTrCP is specific, we first immuno-purified
IL-10R1-Flag from transfected 293T cells in stringent RIPA buffer
that significantly reduces the levels of indirectly pulled-down
proteins [46]. Next, in vitro binding assay was performed by
incubating the IL-10R1-bound beads with lysates from cells
transfected with HA-bTrCP2 (Fig. 1D). Since the interaction of
bTrCP with its substrate is mediated by phosphorylation of the
substrate’s DSG(X)2+nS motif, the immuno-purified IL-10R1 was
also treated with l-phosphatase. As shown in Fig. 1D, the binding
of recombinant HA-bTrCP2 to IL-10R1 was critically dependent
on IL-10R1 phosphorylation, as such was not observed using l-
phosphatase-treated receptor. Such a result also suggests that
transfection of IL-10R1 is sufficient to cause its phosphorylation at
the bTrCP recognition motif(s), in the absence of ligand treatment
or other exogenous stimuli, a scenario similar to that previously
observed with IFNAR1 [35]. We next examined whether the
putative bTrCP-binding site (Ser319/23 in human IL-10R1 or
Ser320/24 in mouse IL-10R1) mediates the receptor’s interaction
with bTrCP. To this end, we performed an in vitro binding assay
using either the immuno-purified wild type (WT) IL-10R1 or its
Ser319/23-to-Ala mutant (2SA). The substitution of these two
conserved serine residues substantially reduced the binding of
recombinant bTrCP2 to IL-10R1 (Fig. 1E), suggesting that the
evolutionarily conserved DSGFGS motif is indeed a bTrCP
recognition site. To directly examine the phosphorylation of
Ser319/23 in IL-10R1, we generated a polyclonal antibody
specific to phosphor-Ser319/23 (or Ser320/24 in mIL-10R1).
Transfected WT IL-10R1, but not the 2SA mutant or the
phosphatase-treated WT IL-10R1, could clearly be recognized by
this antibody, demonstrating that Ser319 and Ser323 are
phosphorylated in ectopically expressed IL-10R1 without ligand
stimulation (Fig. 1F). A similar result was found with murine IL-
10R1 (Figure S1). Additionally, in blots where the mature and
immature forms of IL-10R1 were well separated, we clearly found
that the Ser319, 23 phosphorylation is only associated with the
mature form, but not the immature form (Fig. 1F, right). Such
selective Ser319, 23 phosphorylation of the mature form of IL-
10R1 may have contributed to the preferred binding of bTrCP to
the latter, as seen in Fig. 1C. In sum, the data in Fig. 1 suggest that
bTrCP directly interacts with mature IL-10R1 when the latter is
phosphorylated at Ser319 and Ser323.
It is noteworthy to point out that although phosphorylated
Ser319 and Ser323 are likely to play a major role in the
recruitment of bTrCP, the Ser319/23A IL-10R1 immuno-
purified from the cells was not completely deficient in bTrCP
binding in vitro (lane 3 of Fig. 1E). These results strongly suggest
that the transfected IL-10R1 may possess additional phosphory-
lation-dependent bTrCP- binding site(s). In further surveying the
sequences of IL-10R1 from different species, we identified another
Beta-TrCP Regulates IL-10 Receptor Ubiquitination
PLoS ONE | www.plosone.org 2 November 2011 | Volume 6 | Issue 11 | e27464Figure 1. bTrCP can bind to the DSGFGS motif of IL-10R1. (A) Left: Alignment of some known bTrCP-binding sites together with the putative
bTrCP site in human IL-10R1; right: putative bTrCP-binding sites in IL-10R1 from different species. Serine residues in IL-10R1 that might be equivalent
to those in known bTrCP substrates, whose phosphorylation is required for bTrCP recognition, are underlined in a manner similar to those in the
known substrates. (B) 293T cells transfected with IL-10R1-Flag were subjected to cell surface immunoprecipitation (IP) with the antibody against IL-
10R1 (a10R1) or the isotype control IgG (Istp). Some cell lysates were subjected to regular IP with the antibody against Flag (aFlag). The IPed materials
were analyzed on Western blot. The positions of the 120 kDa and the 100 kDa forms of IL-10R1 were marked by an arrow head and an asterisk
respectively. (C) 293T cells were transfected with IL-10R1-Flag (10R1-Flag) and/or HA-bTrCP2 (HA-BTR2) and were treated with or without IL-10
(10 ng/ml) for 30 min before the lysates were harvested. The lysates were IPed using anti-Flag (left) or anti-HA (right). The IPed materials and the
whole cell extracts (WCE) were analyzed on Western blot using indicated antibodies. The positions of the 120 kDa and the 100 kDa forms of IL-10R1
were marked as in (B). (D) Transfected IL-10R1 was purified from RIPA lysate of 293T cells via immunoprecipitation using Flag antibody. An isotype
(Istp) control antibody IP was used as a negative control. The beads were treated with or without 200 U of l-phosphatase for 30 min and then
incubated at 4 degrees for 1 h with 50 ml of 293T lysates from cells transfected with HA-BTR2. The bound materials were analyzed on Western blot
using indicated antibodies. The input levels of HA-BTR2 with the vector-transfected (Vec) sample as a negative control were shown in the inset. (E)
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369DSGICLQEP) that is conserved
in higher organisms (Fig. 2A). Interestingly, the Glu376 in human
IL-10R1 is represented by Asp372 and by Ser351 in its bovine and
chicken counterparts, respectively. We hypothesized that the
negative charge on the Glu376 residue (or its equivalents in IL-
10R1 from other mammalian species) may have functionally
substituted for a phosphorylated second serine in the canonical
DSG motif, and that bTrCP recruitment via this more membrane-
distal site in mammalian IL-10R1 is triggered by phosphorylation
of Ser370 (or its equivalents). To examine whether such a putative
DSG motif in transfected IL-10R1 contributes to bTrCP binding
in addition to Ser319/23, we generated additional IL-10R1
mutants harboring Ala substitutions at Ser370 alone (Ser370A), or
at Ser319, Ser323 and Ser370 all together (3SA). Immuno-
precipitation (IP) of IL-10R1 mutated at either the upstream (2SA)
or the downstream (S370A) DSG motif yielded reduced levels of
bound HA-bTrCP2 (65% and 43% reduction respectively),
compared to that from the IP of WT IL-10R1 (Fig. 2B).
Importantly, IL-10R1 mutated at both DSG motifs (3SA)
exhibited an even more severe deficiency to co-immunoprecipitate
HA-bTrCP2 (87% reduction, Fig. 2B). These data suggest that the
two DSG motifs in transfected IL-10R1 act in an additive manner
to mediate bTrCP-binding. The latter notion was further
confirmed by the reverse co-IP experiment based on immuno-
precipitation of HA-bTrCP2, which showed that compared to that
of the WT IL-10R1, the efficiency of the 2SA and 3SA IL-10R1 to
be pulled down together with HA-bTrCP2 reduced 61% and
74%, respectively (Fig. 2C). Moreover, a reciprocal IP experiment
using the DSG motif mutants (Ser320/24A and Ser320/24/67A)
of mouse IL-10R1 and HA-bTrCP2 has corroborated the findings
with the human IL-10R1 (Figure S2). Lastly, an in vitro binding
assay using stringently immuno-purified IL-10R1 has shown that
the deficient recruitment of bTrCP by 3SA IL-10R1 was more
severe than that by its 2SA counterpart (Fig. 2D), which serves as
an additional proof for the presence of two functional bTrCP-
binding sites in IL-10R1.
Therefore, the 3SA IL-10R1 represents a more severely affected
bTrCP binding-deficient mutant form. It is interesting to note that
the relative levels of the 3SA IL-10R1 were consistently higher
than those of the WT IL-10R1 in these transient transfection
experiments (Fig. 2B, 2C: Flag immunoblot panels). Moreover,
compared to that of the WT IL-10R1, the mature form of the 3SA
IL-10R1 makes a greater contribution to the abundance of the
total (mature and immature) receptor (Fig. 2B, 2C: ‘m’- and ‘im’-
denoted arrows and the ‘Relative m/im’ values). Importantly,
similar results were obtained when the WT and 3SA IL-10R1
levels were measured using another antibody recognizing the N-
terminus of the protein (Figure S3). Taken together with the data
that bTrCP preferentially binds the mature IL-10R1 (Fig. 1C,
right), these observations suggest that the additive interaction with
bTrCP via both DSG motifs under the context of mature IL-10R1
results in the latter’s down-regulation.
The interaction between bTrCP and IL-10R1 may result in
SCF
bTrCP-dependent IL-10R1 ubiquitination. We used HA-
tagged ubiquitin to examine whether co-transfected IL-10R1 is
constitutively ubiquitinated in cells. A smeared, high-molecular-
weight HA immuno-reactivity characteristic of protein poly-
ubiquitination was observed in denaturing Flag-IL-10R1 IP
(Fig. 3A). Importantly, a smear of Flag immuno-reactivity from
the denaturing IP of HA-ubiquitin was detected in a parallel
experiment, strongly suggesting the direct ubiquitination of IL-
10R1 protein (Fig. 3B). To functionally establish that bTrCP is
responsible for the constitutive ubiquitination of transfected IL-
10R1, we performed bTrCP knockdown experiments. To avoid
artifacts that may be caused by transfection of exogenous
ubiquitin, we focused on examining IL-10R1 modification by
the endogenous ubiquitin. Since Cdc25A is an established target of
SCF
bTrCP [47,48], the efficiency of bTrCP knockdown was shown
by the increased stability of Cdc25A (Fig. 3C, lower panels). As
anticipated, bTrCP knockdown markedly reduced the levels of
constitutive IL-10R1 ubiquitination (Fig. 3C, upper panels). It is
important to note that similar to mutating the bTrCP-binding sites
of IL-10R1 (Fig. 2B, 2C), bTrCP knockdown also led to an
increase in the relative levels of the mature WT IL-10R1, in
comparison to its immature counterpart (Fig. 3C, ‘Flag’ panel and
the values of ‘Relative m/im’). Since ubiquitination of a given
protein often leads to its selected down-regulation, these data
further imply that between the mature and immature forms of IL-
10R1, the former is a preferred target of bTrCP-mediated
ubiquitination.
To examine the cellular location where bTrCP-mediated
constitutive IL-10R1 ubiquitination occurs, we sequentially
enriched the cell surface IL-10R1 (antibody-labeling of live cells)
and its counterpart within the remaining cellular fraction. Cell
surface levels of the bTrCP binding-deficient, 3SA IL-10R1, are
significantly higher than those of WT IL-10R1 after transient
transfection (Fig. 3D left, the panel of ‘Flag w/o calibration’),
consistent with the patterns of the mature IL-10R1 in the whole
cell lysates (Fig. 3D left and Fig. 2B, 2C). After calibration of IL-
10R1 levels, the ubiqitination of cell surface 3SA IL-10R1 was
found to be substantially diminished, compared to that of the cell
surface WT IL-10R1 (Fig. 3D left: the ‘Ub’ panel). These results
indicate that bTrCP binding contributes to the direct ubiquitina-
tion and down-regulation of the cell surface IL-10R1. Interest-
ingly, in the fractions that had the initial antibody-bound IL-10R1
removed (‘Flow-through IP’), the levels of ubiquitinated WT and
3SA IL-10R1 followed a similar pattern (Fig. 3D, right). Although
not exclusively, IL-10R1 within the latter fraction mainly comes
from the intracellular pool. Therefore, these very results imply that
the mature IL-10R1 within the intracellular pool may also
undergo bTrCP-dependent ubiquitination. Nevertheless, it re-
mains possible that a certain portion of the ubiquitinated,
intracellular IL-10R1 results from the endocytic trafficking of the
ubiquitinated cell surface IL-10R1.
Our data thus far indicate that the bTrCP-mediated ubiquitina-
tion of cell surface IL-10R1 leads to its down-regulation. We
examined whether the latter mode of regulation is mediated by a
ubiquitination-dependent enhancement of IL-10R1 endocytosis
that promotes the receptor’s endolysosomal degradation. To
prevent the overloading of the endocytosis and vesicle trafficking
systems by the transiently transfected IL-10R1, 293T cells stably
expressing the WT or the mutant forms of IL-10R1 were used in
experiments analyzing the receptor’s post-ubiquitination fate
(Fig. 4 and Fig. 5). The constitutive endocytic rates of WT IL-
Transfected WT or the S319, 23A (2SA) IL-10R1 was immunopurified from RIPA lysates and then subjected to in vitro binding assay using lysates from
HA-BTR2-transfected cells. (F) WT or 2SA IL-10R1 was IPed from lysates of transfected 293T cells. Left: Some IPed materials were subjected to l-
phosphatase (l-ppts) treatment or left untreated. The levels of Ser319, 23 phosphorylation and of the total IL-10R1 were determined. Right: Results
presented are from a separate blot, where the 120 kDa and the 100 kDa forms of IL-10R1 are clearly discernible. The 120 kDa forms of
phosphorylated and total IL-10R1 are marked by arrow heads.
doi:10.1371/journal.pone.0027464.g001
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PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e27464Figure 2. Identification of an additional bTrCP recognition motif in IL-10R1. (A) Alignment of the second putative bTrCP-binding site in IL-
10R1 from different species. The conserved first serine residue and a second downstream negatively charged residue (or a serine) in such DSG motifs
are underlined. (B) 293T cells were transfected with HA-BTR2 alone, or together with WT, S319, 23A (2SA), S370A or S319, 23, 70A (3SA) IL-10R1.
Lysates were IPed with the Flag antibody. The IP or WCE samples were subjected to Western blot analysis. The relative levels of bTrCP binding to IL-
10R1 were calculated according to the intensities of HA-bTrCP2 signal calibrated by the Flag-IL-10R1 signal. These values were presented by a bar
graph underneath the HA panel of the WCE. Additionally, the relative ratio of abundance between the mature (m) and immature (im) IL-10R1
(pointed respectively by arrows) was determined for the WT or 3SA IL-10R1, and presented under the Flag blot (‘Relative m/im’, with the value of the
WT set to 1.00). (C) Lysates from 293T cells transfected with the WT, 2SA or the 3SA IL-10R1, together with or without HA-BTR2 were IPed using HA
antibody. The levels of bound and total IL-10R1, and levels of the HA-BTR2 were determined by Western blot analysis. The relative levels of IL-10R1
Beta-TrCP Regulates IL-10 Receptor Ubiquitination
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determined using an ELISA-based assay [49] that measures the
kinetic disappearance of pre-labeled, cell surface IL-10R1 after
allowance of its endocytosis (Fig. 4A). Within the time course of
this experiment, the levels of internalized WT and 3SA IL-10R1
both increased over time. Nevertheless, 3SA IL-10R1 was
endocytosed with a much slower rate compared to its WT
counterpart (Fig. 4A). In addition, we adopted a confocal
microscopy-based assay to assess IL-10R1 endocytosis [50]. The
cell surface and intracellular IL-10R1 was stained sequentially
with a green- and red-fluorescent secondary antibody, under
stepwise non-permeant and permeant conditions. Using this
visualizing method, the impaired constitutive endocytosis of 3SA
IL-10R1 was further confirmed by the observation that the
mutant-expressing cells consistently contain fewer and smaller red-
fluorescent spots after being allowed to endocytose membrane
proteins (Fig. 4B: lower two panels). These results strongly suggest
that the bTrCP-mediated ubiquitination of cell surface IL-10R1
promotes its endocytosis.
Lysosomes are the principle cellular organelle responsible for
degradation of the endocytosed membrane proteins [51]. To
follow the turnover of IL-10R1, cells were treated with
cycloheximide to inhibit protein synthesis. Consistent with the
notion that IL-10R1 is degraded via the endolysosomal pathway,
the constitutive decay of the total cellular IL-10R1 was effectively
blocked by a lysosomal inhibitor, methylamine (Fig. 5A). Interest-
ingly, a proteasomal inhibitor, MG132, also partially inhibited IL-
10R1 degradation (data not shown), in agreement with a previous
report [32]. However, since proteasome inhibition can lead to a
myriad of secondary cellular events, including limiting the cellular
pool of free ubiquitin [52,53], we should be cautious not to over-
interpret the latter data. We next proceeded to confirm the role of
bTrCP-dependent ubiquitination of IL-10R1 in mediating its
constitutive degradation. As expected, the shRNA-mediated
knockdown of bTrCP1/2 notably stablized IL-10R1 (Fig. 5B).
To corroborate these data, we also examined the basal turnover of
the WT and the mutant forms of IL-10R1 that are partially (2SA)
and largely (3SA) deficient in bTrCP binding (Fig. 2). As pool-to-
pool variations commonly exist among stable transfectants, it was
not surprising that the steady-state levels of various forms of IL-
10R1 did not strictly follow an inverse relationship to their binding
affinities for bTrCP (Fig. 5C: lane 1, 5 and 9). Nevertheless, the
stability of the 3SA IL-10R1 was the greatest among the group,
followed by that of the 2SA and the WT IL-10R1, sequentially.
Taken together with the data from Fig. 5B, these results indicate
that recruitment of bTrCP via the two DSG motifs of IL-10R1
jointly contributes to the receptor’s constitutive degradation. It is
important to note that neither bTrCP depletion nor mutation at
the DSG motifs led to stabilization of the immature IL-10R1
(Fig. 5B, 5C), reiterating the selective regulation of mature IL-
10R1 by bTrCP. Lastly, we directly measured the basal turnover
of cell surface WT and 3SA IL-10R1 by FACS analysis. Cell
surface levels of the 3SA IL-10R1 were less sensitive to the
cycloheximide-induced down-regulation, as compared to those of
the WT IL-10R1 (Fig. 5D). We conclude that the bTrCP-
mediated ubiquitination of IL-10R1 promotes endocytosis and
subsequent degradation of IL-10R1, whereby regulating the
steady-state cell surface IL-10R1 levels.
As the levels of IL-10R1 correlate with the cellular responsive-
ness to IL-10 [30], we hypothesized that the bTrCP-dependent
modulation of IL-10R1 degradation and abundance can influence
IL-10 function in its target cells. Indeed, compared to that in the
control cells, phosphor-Stat3 (pStat3) induction by IL-10 is more
substantial in cells that had bTrCP knocked down (Fig. 6A).
Similar results were obtained when the levels of IL-10-induced
pStat3 were compared in cells expressing the WT versus the
bTrCP binding-deficient, 3SA IL-10R1 (Fig. 6B). Such enhance-
ment of IL-10 signaling in these two different models harboring
defects of the bTrCP-IL-10R1 degradation axis is apparently
correlated with the higher levels of mature IL-10R1 therein (the
arrow heads in Flag panels, Fig. 6A, 6B). Lastly, we examined
whether the bTrCP-IL-10R1 negative regulatory pathway exists in
immune-related cells. We utilized a mouse macrophage/monocyte
cell line, Raw264.7. These cells have been shown to express a
functional IL-10 receptor [54]. However, we noticed that IL-10
signaling initiated by the endogenous IL-10 receptor was not
sufficient to trigger a marked increase in the activity of a
transfected Stat3-luciferase reporter (Fig. 6C, ‘pcDNA’). Co-
transfection of the WT IL-10R1 with the reporter resulted in the
latter’s sensitivity to IL-10 treatment. Importantly, expression of
the 3SA mutant IL-10R1 poised the cells to exhibit a more robust
induction of Stat3-reporter activity in response to IL-10 (Fig. 6C).
In summary, we have identified a bTrCP-dependent pathway that
can negatively regulate IL-10R1 levels and subsequently, the
magnitude of the cellular responses to IL-10 (Fig. 7). Given the
conservation of the apparent bTrCP recognition motifs within IL-
10R1 from different species, the bTrCP-IL-10R1 axis identified in
the current study may represent an important regulatory pathway
modulating IL-10 function in vivo.
Discussion
We show in the present study that bTrCP can bind to a
318DpSGFGpS and a
369DpSGICLQE motif of IL-10R1 in a
phosphorylation-dependent manner (Figs. 1 and 2), leading to its
ubiquitination (Fig. 3), endocytosis (Fig. 4) and lysosomal
degradation (Fig. 5). Consistently, inhibition of this pathway in
an IL-10R1 ectopic expression system leads to the receptor’s
stabilization (Fig. 5) and up-regulation (Fig. 2B, 2C; Fig 3C, 3D
and Fig. 6A, 6B), which improves the cellular responsiveness to IL-
10 (Fig. 6). Therefore, our data suggest that IL-10R1 may
represent a novel substrate of bTrCP. Nevertheless, further
investigation into the natures of the potential stimuli that may
induce bTrCP-mediated regulation of IL-10R1 is critically needed
to confirm the biological relevance of our findings. Several
possibilities exist. Firstly, although we did not observe IL-10-
dependent recruitment of bTrCP to IL-10R1 in our experimental
system (Fig. 1C), it is formally possible that such an event may be
sufficiently triggered by IL-10 signaling under certain cellular
context. The fact that a previously identified domain (aa282 to
aa389) responsible for IL-10-dependent IL-10R1 down-regulation
in a pro-B cell line encompasses both bTrCP recognition elements
is in agreement with such a notion[32]. Secondly, recent studies in
binding to HA-BTR2 were calculated according to the intensities of bound Flag-IL-10R1 signal calibrated by the total Flag-IL-10R1 signal. These values
were presented by a bar graph below the picture panels. The relative ratio of abundance between the mature and immature WT or 3SA IL-10R1
(‘Relative m/im’, with the value of the WT set as 1.00) is presented under the Flag blot of the WCE samples. (D) 293T cells transfected with the WT, 2SA
or the 3SA IL-10R1 were IPed using Flag antibody in RIPA buffer. The immunoprecipitates were washed extensively and then incubated with the cell
lysates (50 ml) containing HA-BTR2. The levels of the bound HA-BTR2 as well as those of the IPed IL-10R1 were analyzed by Western blot. The levels of
input HA-BTR2 (5 ml) were also presented.
doi:10.1371/journal.pone.0027464.g002
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bTrCP-binding site within a cytokine receptor can indeed be
robustly induced by certain ligand-independent stimuli
[34,37,38,39]. It is rather conceivable that a similar scenario
may apply to IL-10R1, which commits the receptor to degradation
in response to selected physiological or pathological signals. In this
regard, one shall be intrigued by the fact that IL-10R1 indeed
possesses two bTrCP-binding motifs that are conserved in
mammals. More than one bTrCP-binding motif has been
previously identified in Gli/Ci [55,56]. However, unlike the latter
Figure 3. bTrCP mediates IL-10R1 ubiquitination. (A and B) 293T cells were transfected with IL-10R1-Flag and/or HA-ubiquitin (HA-Ub). Samples
were subjected to denaturing IP with Flag (A) or HA (B) antibodies. The IP samples were analyzed for IL-10R1 ubiquitination by Western blot using HA
(A) or Flag (B) antibodies. The positions of the 170 kDa on the immunoblots analyzing ubiquitination were marked by open arrow heads. (C) 293T
cells were transfected with IL-10R1 and shRNA control (shCon) or shRNA against bTrCP1/2 (shBTR). Cellular proteins were subjected to denaturing IP
using Flag antibody and the levels of ubiquitination were analyzed (upper panels). The relative ratio of abundance between the mature and
immature IL-10R1 (‘Relative m/im’, with the value of the control sample set as 1.00) is presented under the Flag blot. In the lower panels, the
degradation kinetics of Cdc25A (another bTrCP substrate) were compared between experiment groups using cycloheximide (CHX) to show the
effectiveness of bTrCP knockdown. (D) 293T cells were transfected with the WT or 3SA IL-10R1. Cells were subjected to cell surface IP first (left panels),
and the remaining fractions were subjected to another round of IP (‘Flow-through IP’, right panels). All natively IPed materials were denatured and
then IPed with the antibody against Flag. For the cell surface IP samples (left panels), the un-calibrated levels of IL-10R1 were determined (‘Flag w/o
calibration’). Next, the adjusted amounts of WT or the 3SA samples were loaded, so that each contains an equivalent level of IL-10R1 (the ‘After
calibration’ bracket). The levels of ubiquitinated cell surface IL-10R1 were analyzed in the calibrated samples. As a control, the IL-10R1 levels within
the WCE samples were shown in the lowest panel. The relative ratios of abundance between the mature and immature forms (‘Relative m/im’, with
the value of the WT set as 1.00) of the WT or the 3SA receptor are presented underneath. In a parallel analysis (right panels), the levels of IL-10R1
ubiquitination were examined from the remaining cellular fractions after the cell surface IP.
doi:10.1371/journal.pone.0027464.g003
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kinases, the serine residues within the two bTrCP-binding sites of
IL-10R1 are surrounded by sequences that show little similarities
between one and the other. We therefore hypothesize that the
phosphorylation of these two DSG motifs is controlled by distinct
kinases, providing the flexibility of regulating receptor degradation
under different conditions. The investigations testing these
hypotheses are currently underway.
Regulation of membrane receptors’ endocytosis and intracellular
sorting by targeted ubiquitination has emerged as a major
regulatory mechanism that determines their abundance and
signaling [57,58]. In regard to ubiquitin-mediated induction of
endocytosis, modification of acceptor lysine residues by either
mono-ubiquition or poly-ubiquitination can be sufficient, depen-
dent on the receptor of the interest and the associated cellular
context [59]. Moreover, it has been established that ubiquitin
moieties conjugated to a given membrane substrate may sufficiently
serve as direct endocytic signals [57], or they may cooperate with
other pre-existing endocytic motifs on the target molecules to
promote endocytosis [60]. It will be of great interest to identify the
acceptor lysine residues on IL-10R1 and the topology of the
conjugated ubiquitin chains, as well as to elucidate their roles in
regulating IL-10R1 endocytosis. In addition to regulation of
endocytosis, ubiquitination of a membrane receptor may also play
an important role in its post-endocytic sorting into the lysosomes
[58]. Whether such a paradigm also applies to the IL-10R1 system
awaits formal elucidation. Following this line of discussion, it is
interesting to point out that the topology of ubiquitin chains driving
the lysosomal sorting can divert from that triggering the upstream
endocytosis event [60,61]. Therefore, potential ubiquitin chain-
editing mechanisms may also contribute to regulating the cellular
destination of the endocytosed IL-10R1 [51]. To summarize, we
believe that our study has provided a basis for follow-up
investigations into the detailed mechanisms regulating distinct
stages of IL-10R1 endocytic trafficking. Such future works may also
improve our knowledge of the fundamental mechanisms that
regulate cell surface receptor trafficking in general.
Our findings add another member of the cytokine receptor
family to the list of bTrCP substrates that has already included
IFNAR1, PRLR, Epo-R and GHR [33,44,45,62]. Cytokine
receptors can be divided into class I and class II, based mainly
on the relative positioning of the four conserved cysteine residues
in the extracellular fibronectin III repeats, together with several
other structural determinants (reviewed in [63]). Of the cytokine
receptors regulated by bTrCP, IL-10R1 and IFNAR1 belong to
the class II cytokine receptor family that currently includes 9 other
members in mammals. Class II cytokine receptors appeared before
invertebrate and vertebrate diversion and expanded rapidly in
early vertebrates. One apparent class II cytokine receptor can be
identified in sea squirt Ciona intestinalis (GI: 198428337)[63] and in
amphioxus Branchiostoma floridae (GI: 260796075 [64]), whereas
zebrafish Danio rerio and pufferfish Tetraodon nigroviridis genomes
encode similar numbers of the class II cytokine receptors
compared to those in the mammalian genomes [63,65]. Impor-
tantly, we have clearly identified putative bTrCP sites in fish
orthologs of IFNAR1 (CRFB5) and IL-10R1 (CRFB7), at positions
similar to those within their counterparts in higher organisms
(Figure S4 and Figure S5). Interestingly, no apparent DSG motifs
can be identified within the putative ancestor form of class II
cytokine receptor from C. intestinalis or B. floridae, or within the
other 9 members of the mammalian class II cytokine receptors.
This suggests that the b-TrCP-dependent regulation of IFNAR1
or IL-10R1 was acquired during their own diversification from
ancestors under the pressure of evolving a sophisticated immune
system [63,65], and such a mode of regulation is likely crucial for
the proper regulation of these receptors during immune responses
elicited by pathogens. It is important to note that from flies to
human, the activation of NF-kB (Dorsal), an essential node of host
defense program, is also under the control of bTrCP (Slimb) that
Figure 4. bTrCP-mediated ubiquitination leads to endocytosis
of IL-10R1. (A) 293T cells stably transfected with the WT IL-10R1 (open
triangles) or the 3SA (black squares) IL-10R1 were subjected to an ELISA-
based endocytosis assay. Cells were allowed to endocytose antibody-
labeled IL-10R1 for the indicated periods of time. The cells were then
incubated with a HRP-conjugated secondary antibody. The amounts of
labeled IL-10R1 remaining on the cell surface were determined by
measuring the cell-associated HRP activity. Two wells were used for
every experimental condition and the average values are presented on
the graph. The error bars depict the range of data from the duplicated
wells. A representative result from one of two independent experiments
is presented. (B) The same cells as in (A) were pre-labeled with IL-10R1
antibody. After being allowed to endocytose the antibody-labeled IL-
10R1 for 45 min, the cells were fixed with paraformaldehyde. The fixed
cells were incubated with an Alexa488-conjugated secondary antibody
to stain the remaining cell surface IL-10R1. Next, the same samples were
permeablized and incubated with a second Cy3-conjugated anti-rat IgG
to stain the endocytosed IL-10R1. The nuclei were labeled with DAPI.
The representative three-color-overlaid pictures of cells expressing WT
or 3SA IL-10R1 before (0’) and after (45’) initiation of endocytosis are
presented (scale bar=10 mm). Since our stable cell line selection
scheme was based on the drug resistance of a co-transfected plasmid,
not all cells expressed IL-10R1. The negatively stained cells serve as
internal controls for the antibody specificity.
doi:10.1371/journal.pone.0027464.g004
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changes in bTrCP levels/activities may coordinately affect the
degradation rate of its multiple substrates [67], it is thus
conceivable that the acquisition of bTrCP-mediated regulation
of IFNAR1 and IL-10R1 in vertebrates would lead to an
additional level of cross-talks among the type I IFN-induced
signaling, the IL-10-dependent signaling and the bTrCP-IkB-NF-
kB axis. This may hypothetically favor the development of a more
balanced immune response against pathogens. Although such a
hypothesis is highly speculative, the apparently selective clustering
Figure 5. bTrCP-mediated ubiquitination drives IL-10R1 degradation. (A) 293T cells stably transfected with IL-10R1 were pretreated for 0.5 h
with or without 20 mM of methylamine (MA); (B) 293T cells stably expressing IL-10R1 were transfected with shCon or shBTR1/2; (C) 293T cells stably
transfected with the WT, S319, 23A (2SA) or S319, 23, 70A (3SA) IL-10R1 were used; (D) 293T cells stably expressing WT or 3SA IL-10R1 were used. In
(A), (B), (C) and (D), all cells were treated with 25 mg/ml of cycloheximide (CHX) for indicated times. In (A), (B) and (C), the levels IL-10R1-Flag in each
sample were determined by immunoblotting. The levels of Cdc25A were used as an indicator of bTrCP knockdown efficiency (B). In (C), band
intensities were determined by NIH ImageJ. Levels of IL-10R1 relative to those of Stat3 (loading control) were calculated and graphed (WT: diamonds;
2SA: squares; 3SA: triangles). In (D), cell surface IL-10R1 levels were determined by FACS analysis. Only cells stained positive for IL-10R1 were gated.
doi:10.1371/journal.pone.0027464.g005
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mitosis, growth regulation, immune regulation, transcriptional
regulation, circadian clock regulation) implies that the substrate
repertoire of bTrCP is not determined randomly during evolution.
Nevertheless, it is obvious that bTrCP binding to IFNAR1 or IkB
is regulated by activation of different upstream kinases attributed
to non-overlapping environmental stimuli [36,68,69]. Likewise, it
should be at least conceivable that phosphorylation of the DSG
motifs of IL-10R1 is regulated by upstream signals that are
relatively independent from those affecting IFNAR1 or IkB.
Taken together, we suggest that multi-layers of selective pressure
have shaped the modes of bTrCP-mediated regulation of IFNAR1
and IL-10R1, which likely contributes to the increased complexity
of immune regulation from invertebrates to vertebrates.
Despite seemly representing an evolutionarily conserved
mechanism, there exists the possibility that the bTrCP-IL-10R1
axis uncovered in the present study may become dys-regulated
under certain conditions of immune imbalance, analogous to what
has been shown in the IFNAR1 system during infections by some
viruses [34,38]. Indeed, decreased IL-10 receptor levels have been
observed in cells derived from rheumatoid arthritis joints [18] or in
cells exposed to a microbial cell wall component, zymosan [19],
although the underlying mechanisms will await further elucida-
tion. Owing to the importance of IL-10 and its receptor in
maintaining the immune homeostasis, we speculate that alterations
in bTrCP-IL-10R1 axis may represent an intriguing possibility
involved in the pathogenesis of certain inflammatory conditions.
Materials and Methods
Plasmids and Reagents
C-terminally Flag-tagged IL-10R1 plasmid used throughout in
the present study was generated via sub-cloning of hIL-10R1
coding sequence from pIRESpuro3-IL-10R1 (a kind gift from Dr.
C Gasche, University of Vienna, Austria [70]) into the pcDNA
vector. The Flag-tagged mIL-10R1 was prepared from MIGR1-
mIL-10R1 vector (a generous gift from Dr. D Yu, University of
Pennsylvania), and also sub-cloned into pcDNA. Mutagenesis was
performed using Takara’s Prime Star DNA polymerase according
to the manufacture instructions. Human bTrCP2 expression
construct in backbone vector pEF was a kind gift from Dr. SY
Fuchs (University of Pennsylvania). The HA-ubiquitin expression
plasmid was generously provided by Dr. Y Yarden (Weizmann
Institute of Science, Israel). M67-luciferase construct was provided
by Dr. JF Bromberg (Memorial Sloan-Kettering Cancer Center).
Renilla luciferase control construct was from Promega. shRNA
vector (pLKO.1) and shRNA control (shC002) was purchased
from Sigma. Hairpin sequence targeting both human bTrCP1 and
2 ([47], GTGGAATTTGTGGAACATC) was cloned into
pLKO.1. Recombinant human IL-10 was purchased from R&D
systems. Cycloheximide was from Sigma. l-phosphatase was
purchased from Santa Cruz. Dual luciferase assay kit was
purchased from Promega.
Cell culture, transfections: 293T cells and Raw264.7 cells were
purchased from ATCC and were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% (v/v)
fetal bovine serum (Hyclone) unless otherwise specified. 293T cells
and Raw264.7 cells were transfected with Lipofectamine 2000
reagent (Invitrogen) and Nano Juice reagent (EMD Chemicals)
respectively. 293T stably expressing IL-10R1 was prepared by
transfecting cells with pcDNA-IL-10R1 together with pLKO.1 (at
a 50:1 ratio), followed by selection with puromycin (1 mg/ml for 3
weeks). Puromycin-resistant clones were pooled and expanded.
Figure 6. Inhibition of bTrCP-mediated IL-10R1 degradation
leads to increased cellular responsiveness to IL-10. (A and B):
293T cells stably expressing IL-10R1 were transfected with shCon or
shBTR1/2 (A); 293T cells were transiently transfected with WT or 3SA IL-
10R1 (B). Cells were treated with 5 ng/ml of IL-10 for indicated times
and the levels of pStat3, Stat3, IL-10R1-Flag were determined by IB. The
bands representing the mature form of IL-10R1 were denoted by arrow
heads in the Flag panels. In (A), the levels of another bTrCP substrate,
Cdc25A, were used to show the effectiveness of bTrCP knockdown. (C)
Raw264.7 cells were transfected with pcDNA, WT or Ser320, 24, 67A
(3SA) mIL-10R1, together with the M67-luciferase reporter construct
and the pCMV-renilla luciferase control. Cells were treated with IL-10
(black bars) or without (open bars) for 6 h and samples were subjected
to dual-luciferase activity assay. Cells were transfected in triplicates.
Average Stat3 reporter activities represented by the relative ratios of
firefly over renilla luciferase activities (fLuc/rLuc) were shown on the
graph, with error bars showing standard deviations. Comparison was
made between IL-10-treated WT versus 3SA groups and the p value was
shown. Data shown are a representative from two independent
experiments.
doi:10.1371/journal.pone.0027464.g006
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percent cells stably expressing IL-10R1.
Immunotechniques: Antibodies against pStat3, Stat3 (Cell
Signaling), against IL-10R1 (polyclonal, C20 or N20), hIL-10R1
(monoclonal, 3F9), Cdc25A, ubiquitin (P4D1), HA tag (Y-11 or
12CA5) from Santa Cruz and against Flag tag and b-actin (Sigma)
were used for immunoprecipitation and immunoblotting. Goat
anti-rabbit and goat anti-mouse secondary antibodies were
purchased from Thermo Scientific. Polyclonal rabbit antibody
against pSer319, 23 of hIL-10R1 (pSer320, 4 of mIL-10R1) was
generated by Signalway Antibody (TX, USA). When not indicated
specifically, cells lysis was performed in buffer containing 1%
Triton-X 100, 0.5% NP-40, 150 mM NaCl, 10 mM Tris-HCl
pH 7.5, 1 mM EDTA, 1 mM NaF, 1 mM sodium orthovanadate,
protease inhibitor cocktail (sigma, 1:500 dilution) and freshly
added 1 mM PMSF. In some experiments, cells were lysed in
RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-
40, 1% sodium deoxycholate, 0.1% SDS with further addition of
EDTA, NaF, sodium orthovanadate, protease inhibitor cocktail
and PMSF, as described above). Immunoprecipitation (IP) was
Figure 7. The major findings of the present study are summarized in a model. IL-10R1 contains two bTrCP-binding sites (
318DSGFGS and
368DSGICLQEP) in its cytoplasmic tail (see the dash-lined box marked by ‘Zoom-in 1’). The phosphorylation of the serine residues within these two
sites can additively trigger recruitment of SCF
bTrCP ubiquitin E3 ligase, resulting in ubiquitination of cell surface IL-10R1 (see the dash-lined boxes
marked by ‘Zoom-in 2’). The ubiquitination of IL-10R1 promotes its endocytosis that expedites the latter’s eventual degradation via the lysosome. The
nature of the physiologically relevant stimuli and of the associated kinase(s) that trigger phophorylation of the two bTrCP-binding sites within IL-10R1
is not known at this point. Nevertheless, in ectopically transfected IL-10R1, these sites appear to be both engaged, which results in the negative
regulation of cell surface IL-10R1 levels. Potentially, under certain physiological/pathological conditions that trigger DSG motifs phosphorylation, the
bTrCP-mediated regulation of cell surface IL-10R1 may play an important role in determining the magnitude of IL-10-mediated Jak/Stat signaling and
transcriptional regulation.
doi:10.1371/journal.pone.0027464.g007
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G agarose (Invitrogen).
For in vitro bTrCP binding assay, the IL-10R1 IPed from the
RIPA lysate was first washed thoroughly with the Triton X-100-
based lysis buffer. l-phosphatase treatment of the washed beads
was carried out at 30 degrees for 30 min, in 20 ml of phosphatase
buffer (50 mM HEPES, pH 7.5, 100 mM EGTA, 5 mM dithio-
threitol, 0.1% BRIJ 35, with freshly added 2 mM MnCl2)
containing 200 units of the enzyme. The reaction was stopped
by placing the samples on ice and the beads were washed with the
Triton X-100 lysis buffer. 50 ml of the lysates from 293T cells
transfected with HA-bTrCP2 was added to the beads and the
slurry was incubated further at 4 degrees for 1 h with constant
agitation. At the end of the incubation, the unbound material was
removed from the beads by washes.
Cell surface immunoprecipitation [71] was performed to enrich
the cell surface IL-10R1 for analysis. Briefly, cells were dissociated
from the plates with PBS containing 1 mM EDTA. After
incubated with 5 mg/ml of the antibody specific to the extracel-
lular domain of IL-10R1 (3F9) on ice, the cell suspension was
washed extensively with PBS. The cell pellets were lysed using the
Triton X-based lysis buffer. Protein G beads were added to the
lysates to pull down the cell surface IL-10R1. In some
experiments, the remaining supernatants were subjected to a
second round of immuno-precipitation to subsequently enrich
intracellular IL-10R1. To examine the levels of direct ubiquitin
modification of IL-10R1, the natively IPed materials were
subjected to denaturing Flag IP (see below).
All protein samples were run on SDS-PAGE gels and were
‘wet’-transferred to PVDF membranes in standard Tris-glycine
buffer. Immuno-blotting analysis was carried out using antibodies
at manufacture suggested dilutions, and the immuno-reactivity
was determined by using chemiluminescent substrate (Millipore).
Denaturing immunoprecipitation
To examine the levels of IL-10R1 ubiquitination, IL-10R1-
containing protein complexes were first IPed under native
conditions. The IPed materials were boiled in 20 ml of denaturing
lysis buffer (50 mM Tris-HCl pH 7.6, 150 mM NaCl and 2%
SDS) for 10 min to break the protein complexes. The samples
were diluted 1:20 using the Triton X-100 lysis buffer (as described
above) and the Flag antibody/protein G beads were added for a
second time to purify the denatured Flag-IL-10R1. When HA-
ubiquitin was co-transfected with the IL-10R1-Flag, a similar
denaturing IP using a monoclonal antibody against HA was used.
Endocytosis assay
A cell surface ELISA-based endocytosis assay [49] was adopted
and slightly modified to measure the ligand-independent endocy-
totic rates of IL-10R1. Briefly, 293T stable transfectants were plated
on poly-D-lysine-coated 24-well plates until reaching confluency.
All subsequent steps were performed on ice and with ice-cold
reagents, unless otherwise specified. Cells were washed in PBS
containing0.66 mMof CaCl2 and 0.33 mMof MgCl2 (PBS++) and
incubated in PBS++ buffer added with 0.5% BSA (PBS++BSA) for
20 min. Cells were then incubated with 5 mg/ml of antibody
specific to the extracellular domain of IL-10R1 (3F9, rat IgG2a,
Santa Cruz) in the PBS++BSA for 45 min. After antibody removal
and washes, cells were added with pre-warmed culture medium and
the plates were placed into the 37-degree incubator to allow IL-
10R1 endocytosis.Afterthespecified periodsoftime,cellswerethen
placed back on ice. After two washes with PBS++, the cells were
incubated with 67 ng/ml of HRP-conjugated secondary antibody
(Santa Cruz) in the PBS++BSA for 30 min. After three washes, cells
were added with 0.1 mg/ml of HRP substrate tetramethylbenzim-
dine (TMB, Sigma) in the substrate solution (0.2 M sodium citrate,
pH 4.0, 0.03% H2O2) and incubated for 15 min. Equal volume of
2NHClwasthenadded toeachwell and thecolordevelopmentwas
measured using a plate reader (SH-1000, Hitachi) under 450 nm.
Cell-associated HRP activity represents the levels of antibody-
labeled IL-10R1 remaining on the cell surface. The values were
calibrated according to the levels of crystal violet staining to control
the variations of cell numbers. The levels of endocytosis were
calculated by the amount of signal loss at each time point relative to
the baseline signal from time 0. Two wells of cells were processed
individually for each experimental condition. The background
signal from samples stained with the control IgG was subtracted
from every sample. The average values and the range of data from
the duplicated samples were graphed.
Confocal microscopy
To visualize the endocytosed IL-10R1, a method described in
[50] was adopted. Cell surface IL-10R1 in 293T stable
transfectants was first pre-labeled with antibody as stated in the
above section. Cells were placed back into the 37-degree incubator
to allow IL-10R1 endocytosis for 45 min. Cells at 0 and 45 min
were fixed on ice with 0.25% PFA in PBS for 1 h. The fixed cells
were then incubated with an Alexa488-conjugated donkey anti-rat
secondary antibody (green, Invitrogen) for 2 h on ice to stain the
remaining cell surface IL-10R1. After washes, cells were then
quickly permeablized with cold methanol to make the endocytosed
IL-10R1 accessible. A second Cy3-conjugated donkey anti-rat
antibody (red, Jackson ImmunoResearch Laboratories) was
subsequently added to the samples to stain the endocytosed IL-
10R1. The coverslips were mounted using an anti-fade reagent
containing DAPI (P36935, Invitrogen). The pictures were taken
under an Olympus FV-1000 confocal microscope and represen-
tative three-color-overlaid pictures were presented.
Flow cytometry
Cells surface levels of transfected IL-10R1 were determined by
staining cells (dissociated using 1x PBS containing 2 mM EDTA)
with anti-IL10-R1 (3F9), in combination with anti-rat-biotin
(Biolegend) and streptoavidin-APC (Biolegend). Cell surface
antigen levels were examined by FACSCaliber flow cytometer
(BD Pharmingen). The data were analyzed by the FlowJo program
(Tree Star).
Luciferase assay
Raw264.7 cells in 24 wells were transfected with pcDNA
(0.075 mg), CMV-rLuc (0.05 mg) and M67-fLuc (0.125 mg) plas-
mids using Nanojuice transfection reagent (EMD Chemicals). On
the next day, cells were treated for 6 h with IL-10 (10 ng/ml) and
harvested using the lysis buffer provided in the Dual-luciferase
assay kit (Promega). Samples were mixed with the Dual-luciferase
substrate in 4 ml round-bottom polystyrene tubes (BD Biosciences)
and the levels of luminescence were determined using Lumat LB
9507 (Berthold Technologies, Germany).
Supporting Information
Figure S1 Phosphorylation of Ser320,4 in transfected
mouse IL-10R1.
(PDF)
Figure S2 Interaction of mouse IL-10R1 with bTrCP is
mediated by Ser320, Ser324 and Ser367.
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Figure S4 Two DSG motifs similar to those found in
human IL-10R1 can be identified in the zebrafish
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Figure S5 A conserved DSGXYS motif is present in the
zebrafish ortholog of IFNAR1.
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